HPV Research
Cervical neoplasia is the abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer. Our work translates into developing and testing novel therapeutics aiming to eradicate persistent human papillomaviruses (HPV) infections in women with established pre-cancerous lesions in clinical trials. This has recently led to the first in-human trial of the world’s broadest HPV vaccine – and is a major milestone in the fight against HPV associated cancers.
Worldwide over 530,000 women are diagnosed with cervical cancer each year.
This is estimated to increase by approximately 2% per annum to 770,000 new cases by 2030.
Cervical cancer is the most common cancer in women under 35.
WHAT IS HPV?
OUR RESEARCH
What's new
Pioneering Project Showcased at Prototypes for Humanity Exhibition in Dubai
5 January 2024
Among the standout projects featured at the Prototypes for Humanity Exhibition in Dubai was the groundbreaking work of our very own Prof. Helen Townley and her student, Ben White. Their project, titled “Radio wave-activated chemotherapy" drew significant attention for its inventive approach to addressing critical issues in cancer treatment....
PRESS
Broadest ever therapeutic HPV vaccine to be tested in clinical trial. Treatment could clear up persistent infections and reduce risk of cervical cancer. Read Guardian article here
Latest publications
-
A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins
Journal article
DORRELL L. et al, (2019), Scientific Reports
-
Journal article
Zheng Y. et al, (2018), Nature Communications, 9
-
Peripheral Basophil Count is Increased in Patients with Endometriosis.
Conference paper
Feng Q. et al, (2018), REPRODUCTIVE SCIENCES, 25, 218A - 218A
-
Journal article
Hancock G. et al, (2018), Best Practice & Research Clinical Obstetrics & Gynaecology, 47, 59 - 72